- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04360226
Assessing the Utility of Peak Inspiratory Flow as a Predictor for COPD Exacerbations
April 9, 2024 updated by: Respiratory Effectiveness Group
This is an international, mulitcentre, observational, prospective study into Peak Inspiratory Flow in COPD patients that aims to: A) Determine the prevalence of suboptimal Peak Inspiratory Flow (PIF) and inadequate inhaler choice and assess the baseline characteristics of these groups.
B) Assess the clinical role of PIF and inhaler choice in predicting COPD exacerbations and symptom burden.
C) Assess the variability and correlation of PIF with other lung function measurements and CAT score in stable COPD.
It is a 12 month study comprising one baseline assessment and 2 follow-up visits at 6 and 12 months.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
400
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sassari, Italy
- University Hospital Sassari
-
-
-
-
-
Hanyang, Korea, Republic of
- Hanyang University Guri Hospital
-
Seoul, Korea, Republic of
- Seoul st. mary's hospital
-
Ulsan, Korea, Republic of
- Ulsan University Hospital
-
-
-
-
-
Valletta, Malta
- Mater Dei Hospital
-
-
-
-
-
Singapore, Singapore
- Singapore General Hospital
-
Singapore, Singapore
- Changi General Hospital
-
-
-
-
-
Ljubljana, Slovenia
- Ljubljana University Medical Centre
-
-
-
-
-
Almeria, Spain
- Hospital University de Torrecárdenas
-
Barcelona, Spain
- University Hospital Vall d'Hebron
-
Granada, Spain
- Hospital Inmaculada HLA
-
Granada, Spain
- HU Virgen de las Nieves
-
Valencia, Spain
- Hospital Universitario de la Ribera
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
COPD patients, who are clinically stable (4 exacerbations in previous 4 weeks) and have been taking inhaled medications for at least 6 months, but have no other chronic respiratory conditions, other than asthma or bronchiectasis.
Description
Inclusion Criteria:
- Spirometry-defined COPD (i.e. post-bronchodilator FEV1/FVC<0.7)
- Age ≥40 years
- Smokers or ex-smokers of at least 10 pack-years
- Clinically stable COPD (no exacerbations in the last 4 weeks)
- Capable of performing serial lung function tests
- Prescribed inhaled medication for at least 6 months
Exclusion Criteria:
- Occurrence of an COPD exacerbation during the previous 4 weeks
- Have any concomitant chronic respiratory condition other than asthma or bronchiectasis (e.g. cystic fibrosis, lung fibrosis, tuberculosis)
- Are unable to understand the instructions of the study or to fill the questionnaires
- Are unwilling to sign the informed consent
- Are participating in a clinical trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of suboptimal PIF and inadequate inhaler choice.
Time Frame: Baseline
|
Determine the prevalence of suboptimal PIF and inadequate inhaler choice.
|
Baseline
|
Exacerbations
Time Frame: 12 months
|
Time to first exacerbation associated with different levels of PIF.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PIF and symptom burden
Time Frame: Baseline, 6 and 12 months
|
PIF measurements will be correlated with COPD Assessment Test (CAT) Scores.
CAT scores range from 0-40 depending on the severity of a persons symptoms; higher scores denote a more severe impact of COPD on a patient's life.
|
Baseline, 6 and 12 months
|
Mortality
Time Frame: 6 and 12 months
|
Annual mortality rate associated with different PIF levels.
|
6 and 12 months
|
Variability and correlation of PIF
Time Frame: Baseline, 6 and 12 months
|
Variability of PIF over time and the correlation between PIF and other lung function measures (including FEV1, FVC, Inspiratory capacity), CAT scores, T2 markers (nasal polyps and dermatitis) and where available blood biomarkers.
|
Baseline, 6 and 12 months
|
Exacerbation rate
Time Frame: 6 and 12 months
|
Annual rate of exacerbations associated with different PIF levels
|
6 and 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Omar Usmani, MD, National Heart and Lung Institute, Imperial College London & Royal Brompton Hosp
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 14, 2020
Primary Completion (Actual)
August 1, 2023
Study Completion (Actual)
January 25, 2024
Study Registration Dates
First Submitted
April 19, 2020
First Submitted That Met QC Criteria
April 21, 2020
First Posted (Actual)
April 24, 2020
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REG-RES1801
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Non-interventional
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States
-
Papworth Hospital NHS Foundation TrustInnovate UK; Cystic Fibrosis Trust; US Cystic Fibrosis FoundationRecruitingCystic FibrosisUnited Kingdom
-
Royal Marsden NHS Foundation TrustRecruiting
-
Regeneron PharmaceuticalsRecruitingHemophilia BUnited States, Germany, United Kingdom, Canada
-
Henri Mondor University HospitalEuropean Society of Intensive Care MedicineRecruitingFournier Gangrene | Necrotizing Soft Tissue Infection | Necrotizing FasciitisFrance
-
Medtronic Cardiac Rhythm and Heart FailureCompleted
-
Eurasian Association of TherapistsCompletedCardiovascular Diseases | Pneumonia | Hypertension | Diabetes | Covid19 | Coronary Heart Disease | Copd | CKD | Overweight and Obesity | SARS-CoV-2 Infection | Cardiac EventRussian Federation
-
DaniscoReprocell Inc; SerologixCompletedHuman MicrobiomeUnited States